Natco Pharma has secured emergency use approval for Baricitinib from India’s Central Drugs Standard Control Organization (CDSCO) for the treatment of Covid-19.

The Indian pharma company has been given the nod for Lilly’s oral JAK1/JAK2 inhibitor in 1mg, 2mg and 4mg strengths in combination with Remdesivir.

Natco Pharma said that it will be seeking a compulsory license based on emergency use and on the basis of grim public health emergency across India because of the second wave of the coronavirus pandemic.

The Hyderabad-based pharma company is ready to release the product this week, in order to make it available to patients suffering from Covid-19 across India.

  baricitinib, CDSCO, Coronavirus, COVID-19, Eli Lilly and Company, Hyderabad, India, Natco Pharma, remdesivir